Browse > Article
http://dx.doi.org/10.3346/jkms.2018.33.e331

Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview  

Kim, Min-A (Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine)
Han, Gwan Hee (Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine)
Kim, Jae-Hoon (Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine)
Seo, Kyung (Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine)
Publication Information
Journal of Korean Medical Science / v.33, no.52, 2018 , pp. 331.1-331.17 More about this Journal
Abstract
Human Papillomavirus (HPV) infection is the most common sexually transmitted infection and is associated with the development of cervical cancer. The purpose of this report is to provide the literature evidences on selecting the HPV vaccine for national immunization program (NIP) in Korea. To complete these tasks, we reviewed domestic and foreign literature on the current status of HPV infection, efficacy and effectiveness of HPV vaccine, safety of vaccine and cost effectiveness analysis of vaccination business. Given that the median age of first sexual intercourse is continuing to fall, this may have serious implications for HPV infection and cervical cancer incidence at the age of 20s. The World Health Organization recommends that the HPV vaccination should be included in the NIP being implemented in each country. Both the bivalent and quadrivalent vaccines have a 90% or greater preventive efficacy on cervical intraepithelial lesion 2-3 and cervical cancer by the HPV 16 or HPV 18. In the future, if HPV vaccination rate as part of NIP increases, it is expected that the incidence of HPV infection, genital warts, and cervical precancerous lesions will be decreased in the vaccination age group. Therefore, in order to increase the HPV vaccination rate at this point in Korea, social consensus and efforts such as the introduction and promotion of HPV vaccine to the NIP according to appropriate cost-effectiveness analysis are required.
Keywords
Human Papillomavirus Infection; National Immunization Program; Vaccination; Cervical Cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309(17):1793-802.   DOI
2 Health Information and Quality Authority (IE). The Role of Human Papillomavirus Vaccines in Reducing the Risk of Cervical Cancer in Ireland. Dublin: Health Information and Quality Authority; 2008.
3 Korea Centers for Disease Control and Prevention. Burden of Human Papillomavirus Infection Related Diseases. Cheongju: Korea Centers for Disease Control and Prevention; 2007.
4 Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28(42):6858-67.   DOI
5 Yamabe K, Singhal PK, Abe M, Dasbach EJ, Elbasha EH. The cost-effectiveness analysis of a quadrivalent human papillomavirus vaccine (6/11/16/18) for females in Japan. Value Health Reg Issues 2013;2(1):92-7.   DOI
6 Korea Centers for Disease Control and Prevention. Prioritization of Introduction to the National Immunization Program. Cheongju: Korea Centers for Disease Control and Prevention; 2010.
7 National Evidence-based Healthcare Collaborating Agency (KR). Economic Evaluation of HPV Vaccination. Seoul: National Evidence-based Healthcare Collaborating Agency; 2013.
8 World Health Organization, Global Advisory Committee on Vaccine Safety. Update on HPV vaccines. http://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en/. Updated 2013. Accessed July 14, 2017.
9 World Health Organization, Global Advisory Committee on Vaccine Safety. Statement on the continued safety of HPV vaccination. http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf?ua=1. Updated 2014. Accessed July 14, 2017.
10 Lee YE, Park JS, Choi EJ. The exact state of female high school students' knowledge about cervical cancer, human papillomavirus vaccination-related health belief and vaccination rate. J Korean Soc Matern Child Health 2013;17(1):27-37.   DOI
11 National Cancer Institute (US). HPV and cancer. Bethesda, MD: National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Risk/HPV/print. Updated 2015. Accessed June 16, 2016.
12 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86.   DOI
13 Weaver BA. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc 2006;106(3 Suppl 1):S2-8.
14 Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.   DOI
15 Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol 2008;18(4):788-94.
16 Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2015. http://ncc.re.kr/cancerStatsView.ncc?bbsnum=438&searchKey=total&searchValue=&pageNum=1. Updated 2018. Accessed June 16, 2016.
17 Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary report. http://www.hpvcentre.net/statistics/reports/XWX.pdf. Updated 2016. Accessed July 14, 2017.
18 Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay. J Korean Med Sci 2012;27(9):1091-7.   DOI
19 Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention, Ministry of Education. The 10th Korea Youth Risk Behavior Web-based Survey. Cheongju: Korea Centers for Disease Control and Prevention; 2014.
20 Han CH, Cho HJ, Lee SJ, Bae JH, Bae SN, Namkoong SE, et al. The increasing frequency of cervical cancer in Korean women under 35. Cancer Res Treat 2008;40(1):1-5.   DOI
21 Choe YJ, Han OP, Cho H, Bae GR, Chun BC, Kim JH, et al. Prioritization of the introduction of new vaccines to the national immunization program in the Republic of Korea. Vaccine 2014;32(46):6049-53.   DOI
22 Statistics Korea. 2016 Annual Report on the Causes of Death Statistics. Daejeon: Statistics Korea; 2016.
23 Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87(7):544-7.   DOI
24 Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst 2014;106(3):djt460.   DOI
25 Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208(3):385-93.   DOI
26 Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis 2013;13(1):75.   DOI
27 Public Health England. Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14: a Review of the Full Six Years of the Three-Dose Schedule. London: Public Health England; 2015.
28 Korea Centers for Disease Control and Prevention. 2014 Infectious Diseases Surveillance Yearbook. Cheongju: Korea Centers for Disease Control and Prevention; 2014.
29 Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, et al. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003;103(3):413-21.   DOI
30 Shin HR, Franceschi S, Vaccarella S, Roh JW, Ju YH, Oh JK, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190(3):468-76.   DOI
31 Kim MA, Oh JK, Chay DB, Park DC, Kim SM, Kang ES, et al. Prevalence and seroprevalence of high-risk human papillomavirus infection. Obstet Gynecol 2010;116(4):932-40.   DOI
32 Lee EJ, Park JS. Knowledge about cervical cancer, health beliefs and human papillomavirus vaccination rate in Female university students. J Korean Onol Nurs 2011;11(1):65-73.   DOI
33 Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43.   DOI
34 Yum JH, Jeong HS, Lee DW, Park KH, Kim NL. Factors Influencing Willingness for human papilloma virus (HPV) vaccination in female students at one university. Korean J Health Promot 2011;11(2):100-5.
35 Bang KS, Sung S, Koo B, Kim M, Kim Y, Kim J, et al. Female university students' HPV-related knowledge and influencing factors on HPV vaccination. J Korean Oncol Nurs 2011;11(3):186-92.   DOI
36 Korea Centers for Disease Control and Prevention. 2013 National Immunization Survey in South Korea. Cheongju: Korea Centers for Disease Control and Prevention; 2013.
37 Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):89-99.   DOI
38 FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27.   DOI
39 Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-70.   DOI
40 Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, Solomon D, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26(37):4795-808.   DOI
41 Erickson BK, Landers EE, Huh WK. Update on vaccination clinical trials for HPV-related disease. Clin Ther 2014;36(1):8-16.   DOI
42 Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30 Suppl 5:F123-38.   DOI
43 Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):100-10.   DOI
44 Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov 2011;1(5):408-19.   DOI
45 FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196(10):1438-46.   DOI
46 Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199(7):926-35.   DOI
47 Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011;7(2):161-9.   DOI
48 Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014;10(5):1155-65.   DOI